<b>Aims:</b> The aim of this study was to quantify how multiple sclerosis (MS) phenotypes differ from each other in respect of costs and quality-of-life.<b>Materials and methods:</b> The study is based on survey data from Finnish patients with MS (<i>n</i> = 553).
<b>Background</b>: Multiple sclerosis (MS) is a neurodegenerative disease caused by dysfunction of the immune system that affects the central nervous system (CNS).
<b>Background:</b> Neurofilament light chain protein (NFL) and chitinase3-like1 (CHI3L1) have gained importance recently as prognostic biomarkers in multiple sclerosis (MS).
<b>Background:</b> Cerebrospinal fluid (CSF) markers of disease in patients with radiologically isolated syndrome (RIS) are the subject of intense investigation, because they have the potential to enhance our understanding of the natural disease course and provide insights into similarities and differences between RIS and other multiple sclerosis (MS) disease identities.
<b>Background:</b> Cerebrospinal fluid (CSF) markers of disease in patients with radiologically isolated syndrome (RIS) are the subject of intense investigation, because they have the potential to enhance our understanding of the natural disease course and provide insights into similarities and differences between RIS and other multiple sclerosis (MS) disease identities.
<b>Conclusion:</b> Our findings reveal a novel pathway from the presentation of Mye-GalCer to IL-17 production, and highlight the promising therapeutic potential of D-sphingosine for the human disorder of multiple sclerosis.
<b>Conclusion:</b><sup>18</sup>F-FAC PET can visualize brain-infiltrating leukocytes in a mouse MS model and can monitor the response of these cells to an immunomodulatory drug.
<b>Conclusions:</b> Our results indicate that TRPV1 influences central inflammation in MS by regulating cytokine release by activated microglial cells.
<b>Interpretation:</b> This is an initial exploration of the utility of CTLA-4, PD-1, TIM-3, LAG-3, and TIGIT expression levels as prognostic indicators in untreated, recently diagnosed multiple sclerosis.
<b>Interpretation:</b> This is an initial exploration of the utility of CTLA-4, PD-1, TIM-3, LAG-3, and TIGIT expression levels as prognostic indicators in untreated, recently diagnosed multiple sclerosis.
<b>Interpretation:</b> This is an initial exploration of the utility of CTLA-4, PD-1, TIM-3, LAG-3, and TIGIT expression levels as prognostic indicators in untreated, recently diagnosed multiple sclerosis.
<b>Introduction</b>: Multiple Sclerosis (MS) is achronic neurological condition that requires costly treatment for aconstellation of motor and sensory symptoms, as well as fatigue, depression, and cognitive problems.
<b>Introduction</b>: Multiple sclerosis (MS) causes focal lesions of immune-mediated demyelinating events followed by slow progressive accumulation of disability.
<b>Methods:</b> In this <i>post-hoc</i> analysis, image- and clinical data of a subset of 24 subjects that were part of a phase IIa clinical trial on the "<b>S</b>afety, Tolerability and Mechanisms of <b>A</b>ction of <b>B</b>oswellic <b>A</b>cids in Multiple Sclerosis (SABA)" (ClinicalTrials.gov, NCT01450124) were included.
<b>Methods:</b> Patients with MS (<i>n</i> = 30), NMOSD (<i>n</i> = 30), and healthy controls (<i>n</i> = 29) underwent visual field (VF), OCT, and mf-ERG testing.